Pindolol augmentation of antidepressants: a review and rationale

References

• Epidemiological field methods in Psychiatry: the Epidemiological Catchment Area Program, WW Eaton, LG Kessler. Academic, New York 1985
   Google Scholar
• Kessler RC, McGonagle KA, Shanyang Z, et al. Lifetime and 12 month prevalence of DSM‐III‐R psychiatric disorders in the United States. Archives of General Psychiatry 1994; 51: 8–19
   PubMed Web of Science ®Google Scholar
• Kiloh LG, Andrews G, Neilson M. The longterm outcome of depressive illness. British Journal of Psychiatry 1988; 153–752; 757
   Web of Science ®Google Scholar
• Lee AS, Murray RM. The longterm outcome of Maudsley depressives. British Journal of Psychiatry 1988; 153: 741–751
   PubMed Web of Science ®Google Scholar
• Burrows GD, Norman TR, Judd FK. Definition and differential diagnosis of treatment resistant depression. International Clinical Psychopharmacology 1994; 2(Suppl. 9)5–10
   Web of Science ®Google Scholar
• Artigas F, Perez V, Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Archives of General Psychiatry 1994; 51: 248–251
   PubMed Web of Science ®Google Scholar
• Blier P, Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. Journal of Clinical Psychopharmacology 1995; 15: 217–222
   PubMed Web of Science ®Google Scholar
• Blier P, Bergeron R, de Montigny C. Selective activation of postsynaptic 5HT1A receptors induces rapid antidepressant response. Neuropsychopharmacology 1997; 16: 333–338
   PubMed Web of Science ®Google Scholar
• Dinan TG, Scott LV. Does pindolol induce a rapid improvement in depressed patients resistant to serotonin reuptake inhibitors?. Journal of Serotonin Research 1996; 3: 119–121
   Google Scholar
• Barkish D, Hooper CL, Thornton MD, Weins A, Miller CA, Thibaudeau CA. Fast onset: an open study of the treatment of major depressive disorder with nefazodone and pindolol combination therapy. International Clinical Psychopharmacology 1997; 12: 91–97
   PubMed Web of Science ®Google Scholar
• Janicak PC, Davis JM, Preskorn SU, Ayd FJ. Principles and Practice of psychopharmacology therapy. Williams and Wilkins, Baltimore 1992
   Google Scholar
• Katona CLE, Robertson MM, Abou Saleh MT, et al. A placebo controlled trial of lithium augmentation of fluoxetine and lofepramine. International Clinical Psychopharmacology 1993; 8: 323–325
   PubMed Web of Science ®Google Scholar
• Thase ME, Rush AJ. Treatment resistant depression. Psychopharmacology: the fourth generation of progress, FE Bloom, DJ Kupfer. Raven Press, New York 1995; 1081–1097
   Google Scholar
• Perez V, Gilaberte I, Faries D, Alvarez E, Artigas F. Randomised, double‐blind, placebo controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 1997; 349: 1594–1597
   PubMed Web of Science ®Google Scholar
• Berman RM, Darnell AM, Miller HL, Anand RA, Charney DS. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double blind, placebo controlled trial. American Journal of Psychiatry 1997; 154: 37–43
   PubMed Web of Science ®Google Scholar
• Tome MB, Isaac MT, Harte R, Holland C. Paroxetine and pindolol: a randomised trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. International Clinical Psychopharmacology 1997; 12: 81–89
   PubMed Web of Science ®Google Scholar
• Bordet R, Thomas P, Dupuis B. Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double‐blind, placebo controlled trial. American Journal of Psychiatry 1998; 55: 1346–1351
   Web of Science ®Google Scholar
• Prien PF, Blaine JO, Levin J. Antidepressant drug therapy: the role of the new antidepressant. Hospital and Community Psychiatry 1985; 36: 513–516
   PubMedGoogle Scholar
• Maas M, Vandoolaeghe E, Desnyder R. Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. Journal of Affective Disorders 1996; 41: 201–210
   PubMed Web of Science ®Google Scholar
• Blier P, de Montigny C, Chaput Y. Modifications of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depression. Journal of Clinical Psychopharmacology 1987; 7: 245–355
   Web of Science ®Google Scholar
• Jacobs BL, Azmitio EC. Structure and function of the brain serotonin system. Physiological Reviews 1992; 72: 165–229
   PubMed Web of Science ®Google Scholar
• Sprouse JS, Aghajanian GK. Electrophysiological responses of serotonergic dorsal raphe neurone responses to 5HT1A and 5HT1B agonists. Synapse 1987; 1: 3–9
   PubMed Web of Science ®Google Scholar
• Hutson PM, Sarna GS, O'Connell MT, Curzon G. Hippocampal 5HT synthesis and release in vivo is decreased by infusion of 8‐OH‐DPAT into the nucleus raphe dorsalis. Neuroscience Letters 1989; 100: 276–280
   PubMed Web of Science ®Google Scholar
• Sharp T, Bramwell SR, Graeme‐Smith DG. 5HT1 agonists reduce 5‐Hydroxytryptamine release in rat hippocampus in vivo as determined by brain microdialysis. British Journal of Pharmacology 1989; 96: 283–290
   PubMed Web of Science ®Google Scholar
• Gartside SE, Umbers V, Sharp T. Inhibition of 5HT cell firing in the DRN by non‐selective 5HT reuptake inhibitors: studies on the role of 5HT1A autoreceptors and noradrenergic mechanisms. Psychopharmacology 1997; 130: 261–268
   PubMed Web of Science ®Google Scholar
• Gobert A, Rivet JM, Cistarelli L, Milan MJ. Potentiation of the fluoxetine induced increase in dialysate levels of serotonin (5HT) in the frontal cortex of freely moving rats by combined blockade of 5HT1A and 5HT1B receptors with WAY 100 635 and GR 127 935. Journal of Neurochemistry 1997; 68: 1159–1163
   PubMed Web of Science ®Google Scholar
• Romero L, Bell N, Artigas F, de Montigny C, Blier P. The effect of pindolol on the function of pre‐ and post‐synaptic 5HT1A receptor: in vivo microdialysis and electrophysiological studies in rat brain. Neuropsychopharmacology 1996; 15: 349–360
   PubMed Web of Science ®Google Scholar
• Hjorth S. (‐)‐ pindolol but not buspirone potentiates the citalopram induced rise in extra cellular 5‐Hydroxytryptamine. European Journal of Pharmacology 1996; 303: 183–186
   PubMed Web of Science ®Google Scholar
• Hjorth S, Jorgan Bengtsson H, Milano S. Raphe 5HT1A autoreceptors but not postsynaptic 5HT1A receptors or β‐adrenoceptors restrain the citalopram induced increase in extracellular 5‐Hydroxytryptamine in vivo. European Journal of Pharmacology 1996; 316: 43–47
   PubMed Web of Science ®Google Scholar
• Dreshfield LJ, Wong OT, Perry KW, Engleman EA. Enhancement of fluoxetine dependent increase of extracellular serotonin (5HT) levels by (‐)‐ pindolol, an antagonist of 5HT1A receptors. Neurochemistry Research 1996; 21: 557–562
   PubMed Web of Science ®Google Scholar
• Chopin P, Moret C, Briley M. Neuropharmacology of 5‐Hydroxytryptamine1B/1D receptor ligands. Pharmacology and Therapeutics 1994; 62: 385–485
   PubMed Web of Science ®Google Scholar
• Hjorth S. Serotonin 5HT1A autoreceptor blockade potentiates the ability of the 5HT reuptake inhibitor citalopram to increase nerve terminal output of 5HT in vivo: a microdialysis study. Journal of Neurochemistry 1993; 60: 776–779
   PubMed Web of Science ®Google Scholar
• Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors: an overview with emphasis on pharmacokinetics and effects of oxidative metabolism. 32. Clinical Pharmacokinetics 1997; 32(Suppl. 1)1–21
   PubMed Web of Science ®Google Scholar
• Brosen K. Recent developments in hepatic drug oxidation: implications for clinical pharmacokinetics. Clinical Pharmacokinetics 1990; 18: 222–239
   Web of Science ®Google Scholar
• Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin reuptake inhibitors on cytochrome P450IID6 (CYP2D6) in human liver microsomes. British Journal of Clinical Pharmacology 1992; 34: 262–265
   PubMed Web of Science ®Google Scholar
• Nemeroff CB, de Vane CL, Pollock BG. Newer antidepresssants and the cytochrome P450 system. American Journal of Psychiatry 1996; 153: 311–320
   PubMed Web of Science ®Google Scholar
• Lock JG, Gwirshman AG, Tang EF. Possible adverse drug interactions between fluoxetine and other psychotropics. Journal of Clinical Psychiatry 1990; 10: 383–384
   Google Scholar
• Goff DC, Midha KK, Brotman AW, Waites M, Baldessarini RJ. Elevation of plasma concentrations of Haloperidol after the addition of fluoxetine. American Journal of Psychiatry 1991; 148: 790–792
   PubMed Web of Science ®Google Scholar
• Centorrino F, Baldessarini RJ, Kando J, et al. Serum ‐ concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate. American Journal of Psychiatry 1994; 151: 123–125
   PubMed Web of Science ®Google Scholar
• Olver JS, Burrows GD. Elevated plasma paroxetine concentrations in a patient treated with a combination of paroxetine and pindolol. International Journal of Psychiatry in Clinical Practice 1998; 2: 225–227
   PubMedGoogle Scholar
• Malhotra S, Santosh PJ. Loading dose imipramine – new approach to pharmacotherapy of melancholic depression. Journal of Psychiatric Research 1996; 30: 51–58
   PubMed Web of Science ®Google Scholar
• Pollock BG, Parel JM, Nathan RS, Kupta DS. Auto antidepressant effect following pulse loading with intravenous and oral clomipramine. Archives of General Psychiatry 1989; 46: 29–35
   PubMed Web of Science ®Google Scholar
• Koran LM, Sullee FR, Pallant S. Rapid benefit of intravenous pulse loading of clomipramine in obsessive‐compulsive disorder. American Journal of Psychiatry 1997; 154: 396–401
   PubMed Web of Science ®Google Scholar